Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
The male breast cancer market is undergoing significant changes in trends, with a growing awareness and focus on this less-known aspect of oncology. In its history, women have been considered as the only victims of breast cancer; however, realization that men can also be affected has led to research and development within the male breast cancer market. This has resulted into increase in cases for the male breast cancer necessitating allocation healthcare resources towards dedicated studies and innovative treatments.
Over the past years, there has been an increase in research initiatives targeting specific aspects of male breast cancer. A number of risk factors that lead to breast cancer have been identified including genetic markers associated with it in males. Consequently, there is a shift from general medicine to personalized medicine with emphasis on targeted therapies tailored for male individuals suffering from different types of cancers. This approach is being pursued by experts diagnosing or treating patients suffering from this form of disease thereby resulting into enhanced overall intervention efficiency.
Advocacy and awareness campaigns about this type of ailment are among other notable developments within this particular industry. For example, efforts to enlighten both the public at large and those in health sector concerning prevalence rates as well as characteristics tied to them have gained momentum. It is important that more people become aware since early detection and timely treatment could minimize mortality rate among men who often reach advanced stages as compared to their female counterparts before diagnosis occurs. Consequently, diagnostic technologies aimed at improving early detection levels through promoting medical attention are experiencing a boom.
Pharmaceutical firms are adjusting their strategies as they respond to emerging issues associated with male breast cancer. There is mounting evidence showing that several drugs currently under development target molecular pathways involved in occurrence of male breast cancer tumors (Drugs.com). These new medications represent a deviation from past practices within their field while confirming commitment by players towards providing innovative solutions for one unique segment brands’ consumers worldwide. As such; clinical trials focusing on men diagnosed with gall bladder cancer are also becoming common place hence; new therapies and improved treatment approaches.
There has been a rise in supportive care measures for male patients with breast cancer, in addition to advances in treatment modalities. To address the unique psychosocial and emotional challenges faced by men diagnosed with breast cancer, healthcare providers have started embracing holistic care. For instance, support groups and counseling services have become part of comprehensive cancer care programs for men with breast cancer to improve their wellbeing.
In spite of these positive trends, there are some challenges affecting the male breast cancer market. However limited awareness among laypersons and medical practitioners about this form of disease acts as a hindrance towards early detection and effective management practices. Fighting such stigma associated with this sickness is however paramount since through so doing; one can talk freely concerning it thus overcoming phobia related to it. Moreover, equal access to healthcare resources as well as information is needed if all men suffering from this type of disease will be given equal opportunity when it comes to receiving adequate treatment options.
Male Breast Cancer Market Highlights:
Global Male Breast Cancer Market Overview
Male Breast Cancer Market Size was valued at USD 1.43 Billion in 2023. The Global Male Breast Cancer industry is projected to grow from USD 1.82 Billion in 2024 to USD 4.03 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 4.27% during the forecast period (2024 - 2032).
Male breast cancer is caused when the breast tissues of males start growing out of control and become cancerous.
Numerous factors such as increasing obese population and growing geriatric population are expected to drive the growth of the market. For instance, in July 2017, the Bristol-Myers Squibb Company announced a broad clinical collaboration with Clovis Oncology for evaluating the combination of cancer drugs Nivolumab and Rucaparib in Phase 2 and Phase 3 clinical trials in multiple tumor types.
Moreover, favorable healthcare expenditures boost the growth of the market. However, lack of knowledge and the high cost of treatments may hamper the market growth during the assessment period.
Male Breast Cancer Market Segmentation
The male breast cancer market has been segmented into type, cancer diagnosis, and treatment.
The market, on the basis of type, has been segmented into, ductal carcinoma in situ, Paget’s disease of the nipple, inflammatory breast cancer, and infiltrating ductal carcinoma.
The market, by diagnosis, has been segmented into, mammography, biopsy, PET scan, CT scan, MRI scan, and other tests. On the basis of diagnosis, biopsy is anticipated to record the largest growth owing to its accuracy of diagnosing the disease. It is also expected to be the fastest growing segment.
By diagnosis, biopsy is further segmented into, fine needle aspiration biopsy, core biopsy, and excisional biopsy.
The market, by treatment, has been segmented into, local treatments and systemic treatments.
By treatment, local treatments are further segment into, surgery and radiation therapy.
Surgery is further segmented into, mastectomy, breast-conserving surgery, and lymph nodes biopsy.
By treatment, systemic treatments are further segmented into, chemotherapy, hormone therapy, and targeted therapy.
Chemotherapy is further segmented into, adjuvant therapy and neoadjuvant therapy.
Hormone therapy is further segmented into, using drugs and orchiectomy (castration).
Targeted therapy is further segmented into, for HER2 positive breast cancer, for hormone receptor-positive breast cancer, and for cancer with BRCA mutations.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The male breast cancer market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European male breast cancer market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The male breast cancer market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The male breast cancer market in the Middle East and Africa has been segmented into the Middle East and Africa.
Male Breast Cancer Market Key Players
Some of the key players in the male breast cancer market are:
- Achieve Life Sciences, Inc.
- Pfizer, Eli Lilly and Company
- Bristol-Myers Squibb Company
- F. Hoffmann-La Roche
- Sanofi
- Novartis AG
- BioNumerik Pharmaceuticals Inc.
- Seattle Genetics, Inc.
- GlaxoSmithKline plc.
- Teva Pharmaceutical Industries Ltd.
- Sun Pharmaceutical Industries Ltd.
- AstraZeneca
- Accord Healthcare
- Bayer AG
Male Breast Cancer Market Regional Analysis
Geographically, the Americas is anticipated to dominate the male breast cancer market owing to the changing lifestyle and rising prevalence of breast cancer. According to an article published by, the American Cancer Society in April 2018, the lifetime risk of getting breast cancer in men is approximately 1 in 833.
Europe is expected to hold the second largest position in the male breast cancer market. The market growth in this region is attributed to the growing prevalence of rare cancers, the availability of funds for research, and increasing healthcare expenditure. According to the Cancer Research UK, 371 new cases of male breast cancer were reported in 2015 in the UK.
Asia-Pacific is anticipated to be the fastest growing region in the market due to the rising awareness regarding early symptoms of cancer and government support for healthcare facilities. According to a study published by the European Society for Medical Oncology in January 2016, there were 4.3 million new cases of cancer in China in 2015.
On the other hand, the Middle East and Africa has the least share of the market. Majority of the market of this region is expected to be held by the Middle Eastern region due to growing government initiatives for the healthcare sector.
Male Breast Cancer Market, by Type
- Ductal Carcinoma in Situ
- Paget’s Disease of the Nipple
- Inflammatory Breast Cancer
- Infiltrating Ductal carcinoma
Male Breast Cancer Market, by Diagnosis
- Mammography
- Biopsy
- Fine Needle Aspiration Biopsy
- Core Biopsy
- Excisional Biopsy
- PET Scan
- CT Scan
- MRI Scan
- Other Tests
Male Breast Cancer Market, by Treatment
BY Treatment
- Local Treatments
- Surgery
- Mastectomy
- Breast-Conserving Surgery
- Lymph Nodes Biopsy
- Radiation Therapy
- Systemic Treatments
- Chemotherapy
- Adjuvant Therapy
- Neoadjuvant Therapy
- Hormone Therapy
- Using Drugs
- Orchiectomy (Castration)
- Targeted Therapy
- For HER2 Positive Breast Cancer
- For Hormone Receptor Positive Breast Cancer
- For Cancer with BRCA Mutations
Male Breast Cancer Market, by Region
- Americas
- North America
- US
- Canada
- South America
- Europe
- Western Europe
- Germany
- France
- Italy
- Spain
- UK
- Rest of Western Europe
- Eastern Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Middle East & Africa
- Middle East
- Africa
Intended Audience
- Breast cancer drug manufacturers
- Breast cancer drug suppliers
- Research and Development (R&D) Companies
- Government and independent research laboratories
- Government and independent regulatory authorities
- Market research and consulting service providers
- Medical research laboratories
- Academic medical institutes and universities
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
